Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ameren (AEE) Shares Outstanding (2016 - 2025)

Ameren has reported Shares Outstanding over the past 17 years, most recently at $276.4 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $276.4 million for Q4 2025, up 2.41% from a year ago — trailing twelve months through Dec 2025 was $276.4 million (up 2.41% YoY), and the annual figure for FY2025 was $276.4 million, up 2.41%.
  • Shares Outstanding for Q4 2025 was $276.4 million at Ameren, up from $270.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding for AEE hit a ceiling of $276.4 million in Q4 2025 and a floor of $255.5 million in Q1 2021.
  • Median Shares Outstanding over the past 5 years was $262.8 million (2023), compared with a mean of $263.9 million.
  • Biggest five-year swings in Shares Outstanding: increased 4.21% in 2021 and later increased 0.35% in 2022.
  • Ameren's Shares Outstanding stood at $257.7 million in 2021, then increased by 1.67% to $262.0 million in 2022, then increased by 1.64% to $266.3 million in 2023, then rose by 1.35% to $269.9 million in 2024, then rose by 2.41% to $276.4 million in 2025.
  • The last three reported values for Shares Outstanding were $276.4 million (Q4 2025), $270.5 million (Q3 2025), and $270.4 million (Q2 2025) per Business Quant data.